


RESEARCH

Open Access



Implementation of second-tier tests in newborn screening for the detection of vitamin B₁₂ related acquired and genetic disorders: results on 258,637 newborns

Sonia Pajares^{1,2}, Jose Antonio Arranz³, Aida Ormazabal^{2,4}, Mireia Del Toro³, Ángeles García-Cazorla^{2,4}, Aleix Navarro-Sastre¹, Rosa María López^{1,5}, Silvia María Meavilla⁴, Mariela Mercedes de los Santos⁴, Camila García-Volpe⁴, Jose Manuel González de Aledo-Castillo¹, Ana Argudo¹, Jose Luís Marín¹, Clara Carnicer³, Rafael Artuch^{2,4}, Frederic Tort^{1,2,5}, Laura Gort^{1,2,5}, Rosa Fernández⁶, Judit García-Villoria^{1,2,5†} and Antonia Ribes^{1,2,5*†} 

Abstract

Background Alteration of vitamin B₁₂ metabolism can be genetic or acquired, and can result in anemia, failure to thrive, developmental regression and even irreversible neurologic damage. Therefore, early diagnosis and intervention is critical. Most of the neonatal cases with acquired vitamin B₁₂ deficiency have been detected by clinical symptoms and only few of them through NBS programs. We aim to assess the usefulness of the second-tier test: methylmalonic acid (MMA), methylcitric acid (MCA) and homocysteine (Hcys) in our newborn screening program and explore the implications on the detection of cobalamin (vitamin B₁₂) related disorders, both genetic and acquired conditions.

Methods A screening strategy using the usual primary markers followed by the analysis of MMA, MCA and Hcys as second tier-test in the first dried blood spot (DBS) was developed and evaluated.

Results During the period 2015–2018 a total of 258,637 newborns were screened resulting in 130 newborns with acquired vitamin B₁₂ deficiency (incidence 1:1989), 19 with genetic disorders (incidence 1:13,613) and 13 were false positive. No false negatives were notified. Concerning the second-tier test, the percentage of cases with MMA above the cut-off levels, both for genetic and acquired conditions was very similar (58% and 60%, respectively). Interestingly, the percentage of cases with increased levels of Hcys was higher in acquired conditions than in genetic disorders (87% and 47%, respectively). In contrast, MCA was high only in 5% of the acquired conditions versus in 53% of the genetic disorders, and it was always very high in all patients with propionic acidemia.

Conclusions When screening for methylmalonic acidemia and homocystinuria, differential diagnosis with acquired vitamin B₁₂ deficiency should be done. The results of our strategy support the inclusion of this acquired condition

[†]Judit García-Villoria and Antonia Ribes have contributed equally to this work

*Correspondence:

Antonia Ribes

aribes@clinic.cat

Full list of author information is available at the end of the article



in the NBS programs, as it is easily detectable and allows the adoption of corrective measures to avoid the consequences of its deficiency.

Keywords Vitamin B₁₂ deficiency, Homocysteine, Methylmalonic acid, Methylcitric acid, Newborn screening, Second-tier test, Methylmalonic acidemia, Propionic acidemia, Homocystinuria

Background

Methylmalonic acidemia, propionic acidemia and homocystinuria, including remethylation defects, are an extensive group of inherited genetic defects included in the expanded newborn screening (NBS) programs in several countries [1, 2].

Methylmalonic acid (MMA), methylcitric acid (MCA) and homocysteine (Hcys) are widely known biomarkers of genetic conditions leading isolated or combined methylmalonic acidemia and homocystinuria [3, 4], or propionic acidemia [5]. However, elevations of MMA, Hcys and MCA can also be the result of secondary alterations, such as acquired vitamin B₁₂ (cobalamin) deficiency [6]. Cobalamin functions in two coenzyme forms: adenosylcobalamine (AdoCbl), which acts as coenzyme in the conversion of methylmalonyl-CoA to succinyl-CoA through methylmalonyl-CoA mutase (EC 5.4.99.2), and methylcobalamine (MeCbl), which acts as coenzyme of methionine synthase (EC 2.1.1.13) in the conversion of Hcys to methionine (Met) with methyltetrahydrofolate, the other essential cofactor of this reaction, converted to tetrahydrofolate in the process [3]. Vitamin B₁₂ must be taken from the diet, particularly from meat, eggs, fish, and milk. Consequently, any alteration of vitamin B₁₂ metabolism, as well as alterations of its absorption, transport, or low intake could cause high levels of MMA and/or Hcys and even MCA accumulation and low levels of Met.

Methylmalonic acidemia and homocystinuria, independently of its origin, can result in anemia, failure to thrive, developmental regression and even irreversible neurologic damage if the deficiency is prolonged [7–13]. Therefore, early diagnosis and intervention is critical. NBS detection is performed through the analysis of propionylcarnitine (C3), Met and the ratios C3/acetylcarnitine (C3/C2) and C3/Met in dried blood spots (DBS). Recently, heptadecanoylcarnitine (C17) has been proposed as new biomarker [14]. However, due to the high rate of false positives using these markers alone, the analysis of second-tier test is required [15–17]. Despite the great contribution of NBS programs to early identification and treatment of these conditions [18–22], most of the neonatal cases with acquired vitamin B₁₂ deficiency have been detected by clinical symptoms and only few of them through NBS programs. Recently reported results of a NBS pilot study recommended the inclusion

of acquired vitamin B₁₂ deficiency in the NBS programs [23, 24].

We aim to assess the usefulness of the second-tier test: MMA, MCA and Hcys in our newborn screening program and explore the implications on the detection of genetic and acquired conditions of vitamin B₁₂ deficiency.

Materials and methods

Subjects, aminoacids and acylcarnitines analysis, as well as organic acid analysis on dried urine spots (DUS) are described in Additional file 1.

Analysis of MMA, MCA, and Hcys on dried blood spots (DBS)

Isotopically labeled MMA and Hcys (MMA-_{d3} and Hcys-_{d8}, respectively) were purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA). MCA and MCA-_{d3} were provided by CDN Isotopes (Pointe-Claire, Quebec, Canada). MMA, Hcys, formic acid and DL-dithiothreitol (DTT) were obtained from Sigma-Aldrich (Saint Louis, USA). Methanol and acetonitrile (LC/MS PAI grade) were obtained from EMD Millipore Corporation (Madrid, Spain). Milli-Q system (Millipore) purified water was used.

Sample preparation

A 4.7 mm disc was punched from each DBS and transferred to a 96-well plate; 175 µL of a solution containing a mix of isotopically labeled standards (0.5 µmol/L Hcys-_{d8}, 1 µmol/L MMA-_{d3}, and, 1 µmol/L MCA-_{d3}), and DTT (42 mmol/L), in Milli-Q water with 0.2% formic acid, were added to each well. The plate was capped and placed into a shaker. Samples were rotated at 1350 rpm for 1 h and then transferred to a clean 96-well filter plate and centrifuged at 4000 rpm for 40 min; 30 µL of the filtered sample were transferred to a clean 96-well round bottom plate, then 120 µL of Milli-Q water containing 0.2% formic acid were added to each well. Once the plate was capped it was ready to inject. A calibration curve of 6 points with spiked concentrations of 0, 5, 10, 20, 50 and 100 µmol/L of Hcys and, 0, 2.5, 5, 12.5, 25 and 50 µmol/L of MMA and MCA on DBS was used for quantification. DBS quality control samples at three concentration levels for each metabolite were analyzed within each batch of samples: 5, 12.5 and 25 µmol/L for Hcys, and 2.5, 6.25 and 12.5 µmol/L for MMA and MCA, respectively.

UPLC-tandem mass spectrometry conditions

MMA, MCA and Hcys on DBS were analyzed by an ultra performance liquid chromatography-tandem mass spectrometry, (UPLC-Xevo TQS Waters, Milford, MA, USA). The chromatographic separation was performed on an Acquity I-Class UPLC with BEH C18 column (2.1 mm x100mm, 1.7 μ m, Waters, Milford, MA, USA). The mobile phase consisted of 0.2% formic acid in water (mobile phase A) and 0.2% formic acid in methanol:water (95:5) (mobile phase B). An isocratic elution at 60°C with 95% mobile phase A (0.2% formic acid in water) and 5% mobile phase B (0.2% formic acid in methanol:water; 95:5) using a flow rate of 0.5 mL/min during 1.5 min was established. The injection volume was 10 μ L.

Mass spectrometer was operated in the electrospray positive ion mode for Hcys and Hcys_{-d8}, and negative ion mode for MMA, and MMA_{-d3}, MCA and, MCA_{-d3}, using multiple reaction monitoring (MRM) mode. Monitored transitions for unlabelled and labeled compounds were: MMA m/z 117 > 73 and m/z 120 > 76; Hcys m/z 136 > 90 and m/z 140 > 94; MCA m/z 205 > 125 and m/z 208 > 128. Nitrogen and argon were used as nebulizing and collision gas, respectively. Dwell time for each transition was 60 ms and the inter-channel delay was 20 ms. Run time was 1.5 min. The following instrumental setting was used: source temperature 150 °C, desolvation temperature 550 °C and capillary voltage 3 kV. Data acquisition and data analysis were performed using MassLynx™ (V3.2) software. The quantification of the compounds was relative to their corresponding internal standards. External calibration curves were used.

Method validation

The method was validated for linearity, limit of detection, limit of quantification, imprecision, accuracy and recovery. Within-day imprecision, between-day imprecision, accuracy and recovery were evaluated by the analysis of quality control samples at three concentration levels: 3, 15 and 40 μ mol/L of MMA; 6, 30 and 80 μ mol/L of Hcys; and 3, 15 and 40 μ mol/L of MCA. The accuracy was expressed as percentage of relative error (results reported in Additional file 2).

Screening approach to the diagnosis

At present our screening panel by tandem MS/MS consists of 20 inherited metabolic (Additional file 3). When screening for propionic acidemia or methylmalonic acidemia and homocystinuria, second-tier tests in the first DBS are necessary to avoid false positive or false negative results. Nonetheless, from 2013 to 2014, second-tier test analysis was not available at our laboratory. Therefore, when primary markers were altered our strategy was to

ask for a second DBS and a DUS. DBS was used to reanalyze the primary markers and DUS to analyze organic acids.

At the end of 2014, we set up the second-tier test method above described. Cut-off values were chosen from our own experience, and the median age was 2,08 days with an interval of 2 to 7 days of age. The developed algorithm is shown in Fig. 1. When any of the primary markers is altered, samples undergo a second-tier test on the same DBS, which includes the simultaneous measurement of MMA, MCA and Hcys. The algorithm shows the classification of samples according to the concentration of second-tier tests in the first DBS. NBS is classified as normal, when all biomarkers are below the cut-off value; as doubtful, when one or more biomarkers show intermediate values and, as altered, when any of the biomarkers is clearly above the corresponding cut-off levels. In doubtful cases a second DBS is requested and primary as well as secondary biomarkers are again performed. In altered cases, newborns are referred to the clinical unit with the corresponding suspected diagnosis (Fig. 1).

To further classify the disease, laboratory testing in urine (MMA, MCA), plasma (total Hcys, MMA, acylcarnitines and aminoacids) and serum (vitamin B₁₂) were assessed. Moreover, the same tests were performed in the mothers. In addition, folate was routinely measured when measuring vitamin B₁₂ in the mothers.

Vitamin B₁₂ deficient patients were treated with 1 mg intramuscular hydroxocobalamin and mothers were either treated or sent to their reference physician to be studied. Control analysis to the child was performed at two weeks post-treatment. The last control was performed at 6 months of age.

Information on feeding modalities, and short-term clinical outcome (presence/absence of clinical symptoms) was documented.

Results

Second-tier tests method validation

The optimized MS parameters in the MRM mode and the chromatographic separation of the compounds are shown in Additional file 4 and Additional file 5, respectively. The method was validated, and results are shown in Additional file 2.

Screening results

As mentioned above, when the second-tier tests were not available at our laboratory, our initial strategy was to ask a second DBS and DUS to the newborns with altered primary markers. In this period (2013–2014) a total of 144,615 newborns were screened, resulting in altered




Fig. 1 Algorithm for the detection of genetic disorders and acquired vitamin B₁₂, from 2015 to nowadays. Cut-off values in μmol/L: C3: initial strategy: < 4.5 (99th ptl); current strategy: 3.5 (96th ptl); Met: 7–35 (1th ptl and 99.7th ptl, respectively); C17: < 0.1 (99.9th ptl); C3/C2 ratio: < 0.2 (99.8th ptl); C3/Met ratio: < 0.43 (99.8th ptl). *Ptl* percentile. *CbIA* methylmalonic acidemia CbIA type, *CbIB* methylmalonic acidemia CbIB type, *CbIC* methylmalonic acidemia with homocystinuria CbIC type, *CbID* methylmalonic acidemia with homocystinuria CbID type, *CbIE* methylmalonic acidemia with homocystinuria CbIE type, *CbIF* methylmalonic acidemia with homocystinuria CbIF type, *CbIG* homocystinuria CbIG type, *CbIJ* methylmalonic acidemia with homocystinuria CbIJ type, *CbIX* methylmalonic acidemia with homocystinuria CbIX type, *CBS* cystathionine β-synthase deficiency, *C17* heptadecanoylcarnitine, *C2* acetylcarnitine, *C3* propionylcarnitine, *Hcys* homocysteine, *MCA* methylcitric acid, *Met* methionine, *MMA* methylmalonic acid, *MS* methionine synthase, *MTHFR* methylenetetrahydrofolate reductase, *MUT* methylmalonyl-CoA mutase deficiency, *NBS* newborn screening, *PA* propionic acidemia

primary markers in 1710 (1.18%) (Fig. 2a), which disclosed a total of 34 cases with alterations, of which 14 were acquired vitamin B₁₂ deficiencies, 2 genetic defects and 1 false positive. The follow-up was lost in 17 newborns. One false negative, diagnosed of methylmalonic acidemia with homocystinuria (CbIC), was notified. The positive predictive value (PPV) for this strategy was 94%.

From 2015 to nowadays, second-tier tests (MMA, MCA and Hcys) were performed on the first DBS. The cut-off of C3 was lowered from 4.5 μmol/L (99th ptl) to 3.5 μmol/L (96th ptl) (Fig. 1). In the period 2015–2018 a total of 258,637 newborns were screened (Fig. 2b), of which 9,889 showed alterations of primary markers (3.8%), disclosing 720 newborns with altered secondary markers, of which 91 presented clearly altered values on the first DBS resulting in 64 acquired vitamin B₁₂ deficiency, 16 were diagnosed with genetic defects and 7 were false positive. The follow-up was lost in 4 newborns. The remaining 629 were found to have intermediate or

doubtful results, and according to our current algorithm, a second DBS was requested. Interestingly, 77 presented clearly altered values on the second DBS, disclosing 66 acquired vitamin B₁₂ deficiency, 3 were diagnosed with genetic defects and 6 were false positive. The follow-up was lost in 2 newborns. In total, the current strategy resulted in 130 newborns with acquired vitamin B₁₂ deficiency among 258,637 newborns screened (incidence 1:1989), 19 with genetic disorders (incidence 1:13,613) and 13 were false positive. No false negatives were notified. Using this strategy, the PPV was 93%.

As a part of the diagnostic work-up the genetic cause of the disease was established in 21 cases (2 cases of the initial strategy and 19 cases of the current strategy) with the following diagnoses: 4 methylmalonic acidemia with homocystinuria (3 CbIC, 1 TCR defect), 7 isolated methylmalonic acidemia (1 CbIA, 1 CbIB and 5 MUT), 1 combined malonic and methylmalonic acidemia (ACSF3), 4 propionic acidemia, 1 SUCLA2 and, 4 homocystinuria




Fig. 2 Results of newborn screening strategies. *DBS* dried blood spot, *DUS* dried urine spot

Table 1 Characteristics and follow up of the patients with genetic diagnosis

Patient	Disease (type)	Mutation		Symptoms before Follow-up or at screening	
		Allele 1	Allele 2		
<i>Initial strategy</i>					
1	MMA (MUT)	c.977G>A	c.977G>A	no	Asymptomatic (7 y 5 m)
2	MMA+Hcys (CblC)	c.271dupA	c.271dupA	yes	Symptomatic (6y 8 m)
<i>Current strategy</i>					
3	MMA+Hcys (CblC)	c.566G>A	c.566G>A	no	Asymptomatic (6 y)
4	MMA+Hcys (CblC)	c.271dupA	c.271dupA	no	Asymptomatic (2y 9 m)
5	MMA (CblA)	c.594dupT	c.594dupT	yes	Asymptomatic (2y 8 m)
6	MMA (CblB)	c.260G>T	c.260G>T	yes	Symptomatic (6y)
7	MMA (MUT)	c.1415C>T	c.1190C>T	no	Asymptomatic (6y)
8	MMA (MUT)	c.655A>T	c.655A>T	yes	Symptomatic (5y 10 m)
9	MMA (MUT)	c.2159_2160delAT	c.2026G>A	no	Asymptomatic (4y)
10	MMA (MUT)	c.983T>C	c.2026G>A	no	Asymptomatic (3y 9 m)
11	Propionic acidemia (PCCA)	c.1409T>G	c.1409T>G	yes	Symptomatic (2y 11 m)
12	Propionic acidemia (PCCA)	c.1370G>A	c.1370G>A	yes	Symptomatic (exitus at 2,5 m)
13	Propionic acidemia	No mutations in PCCA or PCCB		no	Asymptomatic after liver transplant (5y 7 m)
14	Propionic acidemia (PCCB)	c.1218_1231delGGGCATCATCCG GCinsTAGAGCACAGGA	c.1218_1231delGGGCATCAT CCGGCinsTAGAGCACAGGA	yes	Symptomatic (exitus at 12 d)
15	Hcys (CBS)	c.1039G>A	c.1330G>A	no	Asymptomatic (6y)
16	Hcys (CBS)	c.1039+5G>A	c.750G>C	no	Asymptomatic (4y 8 m)
17	Hcys (CBS)	c.1136G>A	c.1330G>A	no	Asymptomatic (4y 2 m)
18	Hcys (CBS)	c.572G>A	c.697T>G	no	Asymptomatic (2y 3 m)
19	MMA+malonic (ACSF3)	c.609T>A	c.1455C>T	yes	Symptomatic (4y 2 m)
20	MMA (SUCLA2)	c.1147C>T	Under study	no	Asymptomatic (3y 3 m)
21	MMA+Hcys (TCR)	c.256_258del	c.256_258del	no	Asymptomatic (3y 2 m)
<i>False negative (initial strategy)</i>					
22	MMA+Hcys (CblC)	c.271dupA	c.566G>A	yes	Asymptomatic 7y 7 m

MMA methylmalonic acidemia, Hcys homocystinuria, CBS Cystathionine Beta-Synthase, TCR transcobalamin receptor, y years, m months

(CBS deficiency). Details on mutations and follow-up of these patients are shown in Table 1. It is interesting to outline that among the Cbl C type patients, including the false negative of the first strategy, the clinical evolution seems not to be dependent on the mutations. It is also interesting to note that 4 out of 5 MUT patients remain asymptomatic. Propionic acidemia is the most severe disease as 3 out of 4 patients had symptoms before screening and two of them died at an early age. Fortunately, the follow-up of the 4 CBS patients showed that all remain asymptomatic.

Results of primary biomarkers on the first blood spot are shown in Table 2A. High C3 was found in a similar percentage both, for genetic or acquired conditions (80% and 81%, respectively). However, C3/C2, C3/Met and C17 were increased in a higher percentage in the group of genetic conditions. Low methionine was recorded in 2 genetic defects (CblC patients) and in 10 cases with acquired vitamin B₁₂ deficiency. High methionine was

Table 2 Altered biomarkers in genetic and acquired conditions

Biomarkers	Genetic conditions		Acquired conditions	
	N/total N	Percentage %	N/total N	Percentage %
<i>(A) Primary biomarkers</i>				
C3	17/21	80	117/144	81
C3/C2	14/21	67	32/144	22
C3/Met	12/21	57	24/144	17
C17	9/21	43	17/144	12
Low Met	2/21	9.5	10/144	7
High Met	3/21	14	2/144	1.4
<i>(B) Second-tier test biomarkers*</i>				
MMA	11/19	58	78/130	60
Hcys	9/19	47	113/130	87
MCA	10/19	53	6/130	5

C3 propionylcarnitine, C2 acetylcarnitine, Met Methionine, C17 heptadecanoylcarnitine, MMA methylmalonic acid, Hcys homocysteine, MCA methylcitric acid, N number of diagnosed cases with altered biomarker, total N total number of diagnosed cases

only detected in 3 genetic cases (CBS deficient patients) and in 2 cases with acquired conditions. DBS results of primary biomarkers by individual groups are shown in Fig. 3; C3 and C3/C2 values were clearly above the cut-off values in MUT, CblA, CblB, CblC, and propionic acidemia while patients with SUCLA2 or ACSF3 defects showed values slightly above the cut-off for both biomarkers. Obviously, C3 and C3/C2 ratio were below cut-off in patients with CBS deficiency (Fig. 3a, b). High Met was characteristic of CBS deficiency whereas, moderate to low values for Met were found in several diseases (Fig. 3c). High values of C3/Met were found in the group of CblC patients and in one patient with acquired B₁₂ deficiency (Fig. 3d); C17, used as an additional primary marker, was very high in propionic acidemia and in some conditions with methylmalonic acidemia (Fig. 3e).

Results of the second-tier test biomarkers are shown in Table 2B, the percentage of cases with MMA above the cut-off levels was very similar, both for genetic or acquired conditions (58% and 60% respectively), but genetic defects showed, in general, highest concentrations of this metabolite (Fig. 4a). Acquired conditions of vitamin B₁₂ deficiency showed 87% of cases with high Hcys (Table 2B), and it was also high in all CblC and in 3 CBS patients but it was below the cut-off values in one CBS patient (9 μmol/L) (Fig. 4b). However, due to the high Met a second DBS was asked, resulting in a clearly high Hcys (68.2 μmol/L). Surprisingly, Hcys was also high in the patient with SUCLA2 defect (Fig. 4b), but it was due to a concomitant dietary deficiency of vitamin B₁₂ in the mother and, consequently, in the newborn.

MCA was high in 53% of the genetic cases (very high in all propionic acidemias, and in some genetic defects) versus 5% of the acquired conditions (Table 2B, Fig. 4c).

Vitamin B₁₂ deficiency on the newborns

The diagnosis of vitamin B₁₂ deficiency was established when vitamin B₁₂ (in blood) was low (<198 pmol/L) and, MMA (in blood or urine) and/or Hcys (in plasma) were elevated. This accounted for 11 patients of the initial strategy and 95 of the current strategy. In addition, 3 patients from the initial strategy and 35 patients from the current strategy were classified as functionally deficient. In these cases, MMA and Hcys were high, while for several reasons vitamin B₁₂ could not be measured in some of the newborns.

Vitamin B₁₂ and Folate on the mothers

All mothers of deficient newborns, underwent vitamin B₁₂ and folate measurement; 57 mothers had a very low vitamin B₁₂ value (<156 pmol/L), 47 had intermediate levels (156–222 pmol/L) and 25 had normal levels. Folate was high in 11 mothers. Interestingly, all of them showed low or very low plasma vitamin B₁₂ concentration.

Demographic data

Demographic data from vitamin B₁₂ deficient cases were obtained from the newborn screening cards. Mother's mean age was 30.5 years (range 18–43), of whom only 11 (7.6%) declare themselves as vegetarians. Regarding the mother's nationality, 38.2% were Spanish, 31.3% Indian or Pakistani, 15.2% from Central and South America, 7.6% from North Africa (mainly Morocco), 4.2% from European countries, and 2.8% from Asia and the Middle East. Data was not available in one case (0.7%).

Cost of the second tier test

Excluding personnel, the cost of test is 6 Euros, it was performed in 3,8% of the newborns resulting in an increase of 59.334 Euros in a total of 258.637 newborns screened. Therefore it results in an additional cost of 0,23 Euros per newborn.

Discussion

The expanded NBS of Catalonia begun in 2013. Diseases included are shown in Additional file 3. Since propionic acidemia, methylmalonic acidemia and homocystinuria were included in our program and primary markers (C3, C3/C2 ratio, Met, C3/Met ratio or, C17) are somehow unspecific, second-tier tests were necessary to avoid false positive or false negative results. Our initial strategy for more than one year was to ask for a second DBS to reanalyze the primary markers and DUS to analyze organic acids (Fig. 2a), but the large number of samples requested for confirmatory testing precluded the long-term use of this strategy.

The setting up of the second-tier test for MMA, MCA and Hcys in a single step in the same DBS was established in our laboratory in 2015, which allowed us to decrease the cut-off values to avoid false negative results, without excessively increasing the number of false positive cases (Fig. 2b). Recently, a German pilot screening has demonstrated the usefulness of the second-tier test for the detection of vitamin B₁₂ deficiencies [24]. These authors use two second-tier strategies of pathways involving vitamin B₁₂ by measuring on the one hand tHcys, and on the other MMA, MCA and 3-hydroxypropionate, while our strategy comprises a single test, which measures three metabolites together (Hcys, MMA and MCA). In addition, our procedure does not use any derivatization step, making the analysis simpler. However, a sensitive MS/MS, such as the one used in this study, is needed to accomplish these measurements.

Quantitative analysis in DBS for MMA, MCA and Hcys was established and validated with good results (Additional file 2). Interestingly, despite using different approaches, results obtained by Gramer et al. [24] were similar to ours, except for a higher incidence of




Fig. 3 Altered values of primary markers on dried blood spots on selected newborns. Y-axis is represented in logarithmic scale. Values are depicted as box-and-whisker plots with minimum and maximum. Dashed lines represents the cut-off values in $\mu\text{mol/L}$: C3: initial strategy: > 4.5 (99th ptl); current strategy: > 3.5 (96th ptl); Met: 7–35 (1th ptl and 99.7th ptl, respectively); C17: > 0.1 (99.9th ptl); C3/C2 ratio: > 0.2 (99.8th ptl); C3/Met ratio: > 0.43 (99.8th ptl). PtI: percentile. *ACFS3* combined malonic and methylmalonic acidemia due to acyl-CoA synthetase family, member 3 deficiency, *B12* vitamin B₁₂ deficient newborns, *CbIA* methylmalonic acidemia CbIA type, *CbIB* methylmalonic acidemia CbIB type, *CbIC* methylmalonic acidemia with homocystinuria CbIC type, *CBS* cystathionine β -synthase deficiency, *C17* heptadecanoylcarnitine, *C2* acetylcarnitine, *C3* propionylcarnitine, *FP* false positive, *Met* methionine, *MUT* methylmalonyl-CoA mutase deficiency, *PA* propionic acidemia, *SUCLA2* beta-subunit of the ADP-forming succinyl-CoA synthetase deficiency, *TCR* transcobalamin receptor defect




Fig. 4 Second-tier test values on dried blood spots in newborns with altered primary markers. *Hcys* homocysteine, *MCA* methylcitric acid, *MMA* methylmalonic acid. Y-axis is represented as logarithmic scale. Values are depicted as box-and-whisker plots with minimum and maximum. Dashed lines represents the cut-off values ($\mu\text{mol/L}$) in the doubtful limit that implies the request of a second DBS: $\text{MMA} > 2.5$; $\text{Hcys} > 7.5$ and $\text{MCA} > 1$. *ACFS3* combined malonic and methylmalonic acidemia due to acyl-CoA synthetase family, member 3 deficiency, *B12* vitamin B₁₂ deficiency, *CblA* methylmalonic acidemia CblA type, *CblB* methylmalonic acidemia CblB type, *CblC* methylmalonic acidemia with homocystinuria CblC type, *CBS* cystathionine β -synthase deficiency, *FP* false positive, *MUT* methylmalonyl-CoA mutase deficiency, *PA* propionic acidemia, *SUCLA2* beta-subunit of the ADP-forming succinyl-CoA synthetase deficiency, *TCR* transcobalamin receptor defect

acquired vitamin B₁₂ deficiency in our population, 1:1,989 or 1:2,722 by excluding 35 newborns in which vitamin B₁₂ was not measured, but with proven functional deficiency. The incidence reported by Gramer et al. [24] was 1:5,355 newborns, which is very close to that reported in Italy (1:5,000) [22] and far away from that reported in Minnesota with a detection rate of 3:100,000 newborns [20]. Recently, an incidence of 1:3,000 newborns in the Estonian screening program has been reported [23], while another recent German study of Munich NBS program revealed a much lower

incidence of vitamin B₁₂ deficiency [25]. Therefore, the incidence of this deficiency differs considerably among NBS programs and it might reflect different strategies used in each program, or even dietetic cultural factors dependent on the nationalities of origin, or other demographic factors. On the other hand, the Italian, Estonian and Municher programs [22, 23, 25] are mainly based on the use of C3 and MMA, while our program and the German pilot screening of Heidelberg [24] are based on the detection of metabolites of both cobalamin dependent pathways. In addition,

the cut-offs used play a relevant role, as exemplified by our two strategies. When using the initial strategy (C3 cut-off: 4.5 $\mu\text{mol/L}$) the percentage of newborns with altered primary markers was 1.18%, while when using the current strategy (C3 cut-off: 3.5 $\mu\text{mol/L}$) the number increased to 3.8%, and decreased to 0.28% when applying the second-tier test in this sample (Fig. 2b). Consequently, the probability to pick-up both, acquired vitamin B₁₂ deficient newborns as well as genetic alterations increases. Interestingly, the pilot study of Gramer et al. [24] speculated that the true incidence of vitamin B₁₂ deficiency in their population might even be higher than it was found, as they only picked up moderate to severe cases of vitamin B₁₂ deficiency. In fact, the results of our NBS program (using the current strategy) support their hypothesis. The higher incidence in our population was probably due to the lowest C3 cut-off, which allowed us to include not only moderate and severe cases but also mild cases. In addition, the incidence of genetic defects was also high, 1:13,612 newborns. Although it should be mentioned that these results included 3 deficiencies (SUCLA2, ACSF3 and TCR), which are not part of our primary panel and could be considered as incidental findings. In these cases, the diagnosis has been reached thanks to the genetic analysis through whole exome sequencing (WES). This methodology is cost-effective as there are 34 genes associated to these diseases. As a consequence, the incidental findings in our NBS program are not rare, but a secondary benefit of these findings is that early treatment can be started in some cases, as it is shown by TCR deficiency resulting in an asymptomatic individual at 3 years of age (Table 1), while in others it will avoid the diagnostic odyssey for the family and facilitate access to adequate genetic counseling [26, 27]. I would like to remark some main points, one is the high frequency of methylmalonic acidemia (MUT) and the modest frequency of methylmalonic acidemia with homocystinuria (CblC type) compared with other studies [28–30], another point is the good evolution of most patients after treatment and several years follow-up (15 out of 21 patients are at present asymptomatic). The worst condition is propionic acidemia, with only one asymptomatic patient, and the best is CBS deficiency being all patients asymptomatic after treatment. Similar results have been reported by Heumer M et al. [31].

Concerning biomarkers, our results showed C3 as the most unspecific marker, both for acquired and genetic defects, (Table 2A) and we agree with other authors [24, 32] that C3 could be not sensitive enough applying conventional cut-offs. It has been reported the ratio C3/C2 as more sensitive than C3 [21, 33]. In our hands, this ratio was more specific than C3, as it is more frequently high

in genetic than in acquired conditions (67% versus 22% respectively, Table 2A). However, the sensitivity of a particular biomarker is dependent on the established cut-off [34]. In our population the cut-off for C3 was 3.5 $\mu\text{mol/L}$, that is quite low, with the purpose to avoid false negative results, as it has been previously described [35, 36]. This strategy, however, implies the analysis of second-tier tests to prevent an excessive number of false positives.

In agreement with Gramer et al. [24] Hcys is the best second-tier biomarker for the detection of acquired vitamin B₁₂ deficiency (Table 2B) and could explain why other programs [20, 22, 25] have found a low number of vitamin B₁₂ deficiencies since they do not use Hcys as second-tier test. In agreement with Hawthorne et al. reflections [37], the measurement of Hcys as second-tier test is an economical way to increase the number of vitamin B₁₂ deficient infants identified, but also of some treatable genetic disorders.

Concerning MCA it has been proven to be a good marker for propionic acidemia as it was always very high in all detected cases. It was also high in some other genetic defects. However, it was found elevated only in few cases with acquired vitamin B₁₂ deficiency (5%) (Table 2B). Consequently, MCA is very helpful to distinguish between both conditions.

Cases with acquired vitamin B₁₂ deficiency were treated according to the established protocol, and thus avoiding the collateral damage associated to this condition. In addition, as a part of diagnostic work-up the genetic cause of the disease was established in 21 patients resulting in 15 asymptomatic individuals after several years of follow-up (Table 1). As a consequence, Screening of vitamin B12 deficiency has been incorporated in our screening program. In addition, the Autonomous Government of Catalonia recommended to avoid low B12 ingestion during pregnancy [38].

Regarding the hypothesis of Selhub et al. [39] on the adverse effects of folate supplementation on the metabolism of vitamin B₁₂, we have not been able to establish a statistically significant relationship, as high serum folate and low vitamin B₁₂ was only found in 11 mothers.

Conclusions

The inclusion of MMA, MCA and Hcys as second-tier test in our NBS program was successful in detecting both, acquired vitamin B₁₂ deficiency and genetic defects, with an incidence of 1:1.989 and 1:13,612 newborns, respectively.

Inclusion of second-tier test in our NBS program decreased drastically the recall rate due to false positive results of primary markers. On the other hand, it allowed us to decrease the cut-off of primary markers to avoid false negative results.

The best second-tier marker for acquired vitamin B₁₂ deficiency was Hcys, and when MCA is high, it points to a genetic defect rather than acquired conditions. However, despite certain trends that point more to one condition than the other, it is not possible to distinguish between them in absolute terms. In these cases, the assessment of vitamin B₁₂ will help to establish the differential diagnosis.

NBS programs including methylmalonic acidemia and homocystinuria should also include the screening of acquired vitamin B₁₂ deficiency, since the benefits of its detection perfectly meet the criteria of Wilson and Junger [40]. Therefore, screening for vitamin B₁₂ deficiency has been incorporated in our screening program.

Abbreviations

ACSF3	Acyl-CoA synthetase family member 3
CblA	Methylmalonic acidemia CblA type
CblB	Methylmalonic acidemia CblB type
CblC	Methylmalonic acidemia with homocystinuria CblC type
CBS	Cystathionine β-synthase
C17	Heptadecanoylcarnitine
C2	Acetylcarnitine
C3	Propionylcarnitine
DBS	Dried blood spot
DUS	Dried urine spot
Hcys	Homocysteine
Hcys ^{-d8}	DL-homocysteine (3,3,3',3',4,4,4',4'-d ₈)
MCA	Methylcitric acid
MCA ^{-d3}	2-Methyl ^{-d₃} -citric acid
Met	Methionine
MMA ^{-d3}	Isotopically labeled methylmalonic acid
MMA	Methylmalonic acid
MS/MS	Tandem mass spectrometry
MUT	Methylmalonyl-CoA mutase
NBS	Newborn screening
SUCLA2	Beta-subunit of the ADP-forming succinyl-CoA synthetase deficiency
TCR	Transcobalamin receptor

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13023-021-01784-7>.

Additional file 1. Additional material and methods.

Additional file 2. Validation results of methylmalonic acid, methylcitric acid and homocysteine on dried blood spots by UPLC-MS/MS.

Additional file 3. Diseases included in the neonatal screening program of Catalonia.

Additional file 4. Mass spectrometer parameters for the detection of methylmalonic acid, homocysteine, and methylcitric acid.

Additional file 5. MRM of the extracted ion chromatograms of methylmalonic acid homocysteine and methylcitric acid together with the corresponding deuterated compounds.

Acknowledgments

Thanks are due to E. Flores, C. Martínez, G. Delgado, C. Fernández, Y. Quintero, T. Collado, S. Richard, P. Alcalá and, M. Fernández for their excellent technical assistance in the acylcarnitine, second-tier test and organic acid analysis.

Authors' contributions

All the authors contributed to the conceptualization and design of the study. All of them approved the final manuscript. SP contributed to the selection of the patients, data curation, formal analysis and wrote the initial manuscript. AN performed and validated the second tier-test methodology. JLM, RML and AA contributed to the data curation. JMG contributed to the data curation and formal analysis. JAA, CC, AO and RA performed the biochemical confirmatory tests in newborns and mothers. FT and LG performed the genetic studies. MDT, AGC, SMM, MMDS and CGV performed the clinical evaluation and follow up of the newborns referred to the Clinical Units. RF performed the follow up of these patients from the public health agency. JGV and AR critically reviewed the subsequent drafts of the manuscript.

Funding

This research was supported, in part, by the Instituto de Salud Carlos III (P119/01310) and co-funded by European Union (ERDF, "A way to make Europe"), the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), an initiative of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovación, Spain). This study was also supported by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR, 2017:SGR 1428) and the CERCA Programme/Generalitat de Catalunya.

Availability of data and materials

Available on request.

Declarations

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Approved.

Author details

¹Sección de Errores Congénitos del Metabolismo-IBC, Servicio de Bioquímica Y Genética Molecular, Hospital Clínic de Barcelona, C/ Mejía Lequerica S/N, Edificio Helios III, 08028 Barcelona, Spain. ²Center for Biomedical Research Network on Rare Diseases (CIBERER), Madrid, Spain. ³Unit of Metabolic Diseases, Hospital Vall D'Hebrón, Barcelona, Spain. ⁴Inborn Errors of Metabolism Unit, Hospital Sant Joan de Déu, Barcelona, Spain. ⁵Biomedical Research Institute, August Pi I Sunyer (IDIBAPS), Barcelona, Spain. ⁶Maternal and Child Health Service, Public Health Agency of Catalonia, Health Department, Government of Catalonia, Barcelona, Spain.

Received: 12 January 2021 Accepted: 16 March 2021

Published: 30 April 2021

References

1. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, et al. Current status of newborn screening worldwide: 2015. *Semin Perinatol.* 2015;39:171–87.
2. Garcia-Villoria J, Pajares S, López RM, Marin JL, Ribes A. Neonatal Screening for Inherited Metabolic Diseases in 2016. *Semin Pediatr Neurol.* 2016;23:257–72.
3. Fowler B, Leonard JV, Baumgartner MR. Causes of and diagnostic approach to Methylmalonic acidurias. *J Inher Metab Dis.* 2008;31:350–60.
4. Huemer M, Kožich V, Rinaldo P, Baumgartner MR, Merinero B, Pasquini E, et al. Newborn screening for homocystinurias and Methylation disorders: systematic review and proposed guidelines. *J Inher Metab Dis.* 2015;38:1007–19.
5. Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. *Orphanet J Rare Dis.* 2014;9:13.

6. Whitehead VM. Acquired and inherited disorders of cobalamin and folate in children. *Br J Haematol.* 2006;134:125–36.
7. Kuhne T, Rubl R, Baumgartner R. Maternal vegan diet causing a serious infantile neurological disorder due to vitamin B12 deficiency. *Eur J Pediatr.* 1991;150:205–8.
8. Graham SM, Arvela OM, Wise GA. Long-term neurologic consequences of nutritional vitamin B12 deficiency in infants. *J Pediatr.* 1992;121:710–4.
9. Rasmussen SA, Fernhoff PM, Scanlon KS. Vitamin B12 deficiency in children and adolescents. *J Pediatr.* 2001;138:10–7.
10. Weiss R, Fogelman Y, Bennett M. Severe vitamin B12 deficiency in an infant associated with a maternal deficiency and a strict vegetarian diet. *J Pediatr Hematol Oncol.* 2004;26:270–1.
11. Korenke GC, Hunneman DH, Eber S, Hanefeld F. Severe encephalopathy with epilepsy in an infant caused by subclinical maternal pernicious anaemia: case report and review of the literature. *Eur J Pediatr.* 2004;163:196–201.
12. Jain R, Singh A, Mittal M, Talukdar B. Vitamin B12 deficiency in children: a treatable cause of neurodevelopmental delay. *J Child Neurol.* 2015;30:641–3.
13. Singh G, Le D, Schnabl K, Leaker MT, Steele M, Sparkes RL. Vitamin B12 deficiency in infancy: the case for screening. *Pediatr Blood Cancer.* 2016;63:740–2.
14. Malvagia S, Haynes CA, Grisotto L, Ombrore D, Funghini S, Moretti E, et al. Heptadecanoylcarnitine (C17) a novel candidate biomarker for newborn screening of propionic and Methylmalonic acidemias. *Clin Chim Acta.* 2015;450:342–8.
15. La Marca G, Malvagia S, Pasquini E, Innocenti M, Donati MA, Zammarchi E. Rapid 2nd-tier test for measurement of 3-OH-propionic and methylmalonic acids on dried blood spots: reducing the false positive rate for propionylcarnitine during expanded newborn screening by liquid chromatography-tandem mass spectrometry. *Clin Chem.* 2007;53:1364–9.
16. Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004–2007). *J Inherit Metab Dis.* 2007;30:585–92.
17. Monostori P, Klinke G, Richter S, Barath A, Fingerhut R, Baumgartner MR, et al. Simultaneous determination of 3-hydroxypropionic acid, methylmalonic acid and methylcitric acid in dried blood spots: second-tier LC-MS/MS assay for newborn screening of propionic acidemia, methylmalonic acidemias and combined remethylation disorders. *PLoS ONE.* 2017;12:e0184897.
18. Marble M, Copeland S, Khanfar N, Rosenblatt DS. Neonatal vitamin B12 deficiency secondary to maternal subclinical pernicious anemia: identification by expanded newborn screening. *J Pediatr.* 2008;152:731–3.
19. Hinton CF, Ojodu JA, Fernhoff PM, Rasmussen SA, Scanlon KS, Hannan WH. Maternal and neonatal vitamin B12 deficiency detected through expanded newborn screening—United States, 2003–2007. *J Pediatr.* 2010;157:162–3.
20. Sarafoglou K, Rodgers J, Hietala A, Matern D, Bentler K. Expanded newborn screening for detection of vitamin B12 deficiency. *JAMA.* 2011;305:1198–200.
21. Yahyaoui R, Dayaldasani A, Rueda I, Blasco J, Serrano J, Navas VM, et al. Detection of vitamin B12 deficiency using expanded newborn screening in eastern Andalucía. *Spain J Inherit Metab Dis.* 2012;35:s160–s160.
22. Scolamiero E, Villani GR, Ingenito L, Pecce R, Albano L, Caterino M, et al. Maternal vitamin B12 deficiency detected in expanded newborn screening. *Clin Biochem.* 2014;47:312–7.
23. Reinson K, Kunnasap K, Kriisa A, Vals MA, Muru K, Ounap K. High incidence of low vitamin B12 levels in Estonian newborns. *Mol Genet Metab Rep.* 2018;15:1–5.
24. Gramer G, Fang-Hoffmann J, Feyh P, Klinke G, Monostori P, Mütze U, et al. Newborn screening for vitamin B12 deficiency in Germany—strategies, results, and public health implications. *J Pediatr.* 2020;216:165–72.
25. Weiss KJ, Röschinger W, Blessing H, Lotz-Havla AS, Schiergens KA, Maier EM. Diagnostic challenges using a 2-tier strategy for methylmalonic acidurias: data from 1.2 million dried blood spots. *Ann Nutr Metab.* 2020;1–9.
26. Pajares S, López RM, Gort L, Argudo-Ramírez A, Marín JL, González de Aledo-Castillo JM, et al. An incidental finding in newborn screening leading to the diagnosis of a patient with *ECHS1* mutations. *Mol Genet Metab.* 2020;22:100553.
27. Yahyaoui R, Blasco-Alonso J, Gonzalo-Marín M, Benito C, Serrano-Nieto J, González-Gallego I, et al. Metabolic serendipities of expanded newborn screening. *Genes.* 2020;11:1018.
28. Nogueira C, Aiello C, Cerone R, Martins E, Caruso U, Moroni I, Rizzo C, et al. Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC type. *Mol Genet Metab.* 2008;93(4):475–80.
29. Richard E, Jorge-Finnigan A, Garcia-Villoria J, Merinero B, Desviat LR, Gort L, et al. Genetic and cellular studies of oxidative stress in methylmalonic aciduria (MMA) cobalamin deficiency type C (cblC) with homocystinuria (MMACHC). *Hum Mutat.* 2009;30(11):1558–66.
30. Yang N, Gong LF, Zhao JQ, Yang HH, Ma ZJ, Liu W, et al. Inborn errors of metabolism detectable by tandem mass spectrometry in Beijing. *J Pediatr Endocrinol Metab.* 2020;33(5):639–45.
31. Huemer M, Kožich V, Rinaldo P, Baumgartner MR, Merinero B, Pasquini E, Blom HJ, et al. Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. *J Inherit Metab Dis.* 2015;38(6):1007–19.
32. Campbell CD, Ganesh J, Ficioglu C. Two newborns with nutritional vitamin B12 deficiency: challenges in newborn screening for vitamin B12 deficiency. *Haematologica.* 2005;90:ECR45.
33. Armour CM, Brebner A, Watkins D, Geraghty MT, Chan A, Rosenblatt DS. A patient with an inborn error of vitamin B12 Metabolism (cblF) detected by newborn screening newborn screening. *Pediatrics.* 2013;132(1):e257–61.
34. Estrella J, Wilcken B, Carpenter K, Bhattacharya K, Tchan M, Wiley V. Expanded newborn screening in New South Wales: Missed cases. *J Inherit Metab Dis.* 2014;37:881–7.
35. la Marca G, Malvagia S, Casetta B, Pasquini E, Donati MA, Zammarchi E. Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany: update on methods to reduce false tests. *J Inherit Metab Dis.* 2008;31(2):S395–404.
36. Al-Dirbashi OY, McIntosh N, McRoberts C, Fisher L, Rashed MS, Makhseed N, et al. Analysis of methylcitrate in dried blood spots by liquid chromatography-tandem mass spectrometry. *JIMD Rep.* 2014;16:65–73.
37. Hawthorne BS, Levy HL. Can newborn screening for vitamin B₁₂ deficiency be incorporated into all newborn screening programs? *J Pediatr.* 2020;216:9–10.
38. Pregnancy monitoring protocol in Catalonia. 3rd ed. Health Department. Government of Catalonia. Available from: https://scientiasalut.gencat.cat/bitstream/handle/11351/1204/protocol_seguint_embaras_catalunya_2018.pdf?sequence=14.
39. Selhub J, Morris MS, Jacques PF. In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. *Proc Natl Acad Sci USA.* 2007;104:19995–20000.
40. Wilson JMG, Jungner G and World Health Organization. Principles and practice of screening for disease. Geneva: WHO; 1968. Available from: <https://apps.who.int/iris/handle/10665/37650>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.